28 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Here's Why Investors Should Follow Sanofi and GlaxoSmithKline's New Coronavirus Collaboration https://www.fool.com/investing/2020/04/30/heres-why-investors-should-follow-sanofi-and-glaxo.aspx?source=iedfolrf0000001 Apr 30, 2020 - The combined effort of these two companies marks one of the largest manufacturing collaborations on the planet toward a coronavirus vaccine.
Glaxo (GSK) Q1 Earnings Beat on COVID-19-Related Stockpiling http://www.zacks.com/stock/news/900859/glaxo-gsk-q1-earnings-beat-on-covid-19-related-stockpiling?cid=CS-ZC-FT-analyst_blog|earnings_article-900859 Apr 30, 2020 - Glaxo (GSK) beats on earnings and sales in the first quarter. Strong demand for respiratory drugs and Shingrix along with stockpiling of certain drugs amid COVID-19 drive sales.
GlaxoSmithKline plc (GSK) Q1 2020 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/04/29/glaxosmithkline-plc-gsk-q1-2020-earnings-call-tran.aspx?source=iedfolrf0000001 Apr 29, 2020 - GSK earnings call for the period ending March 31, 2020.
GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q1 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4341162-glaxosmithkline-plc-gsk-ceo-emma-walmsley-on-q1-2020-results-earnings-call-transcript?source=feed_sector_transcripts Apr 29, 2020 -
Healthcare ETFs to Gain on Progress in Coronavirus Vaccine http://www.zacks.com/stock/news/899331/healthcare-etfs-to-gain-on-progress-in-coronavirus-vaccine?cid=CS-ZC-FT-etf_news_and_commentary-899331 Apr 29, 2020 - The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.
What's in Store for Innoviva (INVA) This Earnings Season? http://www.zacks.com/stock/news/894884/whats-in-store-for-innoviva-inva-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-894884 Apr 28, 2020 - Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the first quarter.
Is a Beat in Store for Perrigo (PRGO) This Earnings Season? http://www.zacks.com/stock/news/891904/is-a-beat-in-store-for-perrigo-prgo-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-891904 Apr 27, 2020 - Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Sanofi (SNY) Q1 Earnings, Sales Grow on Coronavirus-Led Buying http://www.zacks.com/stock/news/887312/sanofi-sny-q1-earnings-sales-grow-on-coronavirus-led-buying?cid=CS-ZC-FT-analyst_blog|earnings_article-887312 Apr 24, 2020 - Sanofi (SNY) beats estimates for both earnings and sales. Around half of the sales and earnings growth at CER was due to COVID-19 associated patient stockpiling. Stock down.
Will Gilead (GILD) Beat Q1 Earnings Despite Coronavirus Mayhem? http://www.zacks.com/stock/news/887588/will-gilead-gild-beat-q1-earnings-despite-coronavirus-mayhem?cid=CS-ZC-FT-analyst_blog|earnings_preview-887588 Apr 24, 2020 - Investors will focus on the HIV franchise's performance along with updates on experimental coronavirus treatment, when Gilead (GILD) reports first-quarter 2020 results.
Is a Beat in Store for Glaxo (GSK) This Earnings Season? http://www.zacks.com/stock/news/887540/is-a-beat-in-store-for-glaxo-gsk-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-887540 Apr 24, 2020 - Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the first quarter. Results will provide clarity on the impact of coronavirus on the company's business.

Pages: 123

Page 1>